In yesterday’s Wall Street session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) shares traded at $1.75, down -9.79% from the previous session.
LXRX stock price is now -3.85% away from the 50-day moving average and 5.03% away from the 200-day moving average. The market capitalization of the company currently stands at $632.61M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $5, Leerink Partners recently initiated with Outperform rating for Lexicon Pharmaceuticals Inc (NASDAQ: LXRX). On March 07, 2023, Jefferies recently initiated its ‘Hold’ rating on the stock quoting a target price of $3, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, COATS LONNEL, Chief Executive Officer bought 90,000 shares of the company’s stock on Nov 16 ’23. The stock was bought for $94,797 at an average price of $1.05. Upon completion of the transaction, the Chief Executive Officer now directly owns 914,359 shares in the company, valued at $1.6 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 10 ’23, Chief Executive Officer COATS LONNEL bought 10,000 shares of the business’s stock. A total of $10,100 was incurred on buying the stock at an average price of $1.01. This leaves the insider owning 824,359 shares of the company worth $1.44 million. A total of 4.13% of the company’s stock is owned by insiders.
During the past 12 months, Lexicon Pharmaceuticals Inc has had a low of $0.92 and a high of $3.73. As of last week, the company has a debt-to-equity ratio of 0.37, a current ratio of 15.58, and a quick ratio of 15.56. The fifty day moving average price for LXRX is $1.8156 and a two-hundred day moving average price translates $1.66635 for the stock.
The latest earnings results from Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) was released for 2024-03-31. The net profit margin was -8311.12% and return on equity was -101.92% for LXRX. The company reported revenue of $1.13 million for the quarter, compared to $24000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4608.33 percent.
